Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.

Related Keywords

Qatar ,United States ,Netherlands ,Bahrain ,Saudi Arabia ,France ,Israel ,Kuwait ,United Arab Emirates ,Woman ,Omani ,Americans ,Omanis ,Kingdom Of Saudi Arabia ,Yutaka Niihara ,George Sekulich ,Willis Lee ,National Center On Birth Defects ,Exchange Commission ,Emmaus Life Sciences Inc ,Blueprint For Action National Academy Of Sciences ,Global Commercialization Of Emmaus Life Sciences Inc ,Committee On Addressing Sickle Cell Disease ,Centers For Disease ,Emmaus Life Sciences ,Company Contact ,Chief Executive Officer ,Senior Vice President ,Global Commercialization ,Life Sciences ,Prescribing Information ,Sickle Cell Disease ,National Center ,Birth Defects ,Developmental Disabilities ,Disease Control ,Addressing Sickle Cell Disease ,Strategic Plan ,Sciences Press ,Private Securities Litigation Reform Act ,